COMMUNIQUÉS West-GlobeNewswire

MemoTril Consumer Concerns Under Investigation: Critiquing The Memo Tril Claims
09/03/2026
A 2026 consumer research report examining MemoTril marketing claims, ingredient transparency, refund policies, manufacturing disclosures, and verification considerations for adults researching cognitive support [...]
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
09/03/2026
Please see enclosed pdf. Attachment 09032026_trading_in_shares_NBC
FocusMax Cognitive Support Claims Evaluated: Latest 2026 Consumer Research Report on FocusMax Ingredients, Proprietary Blend Dosing, and Cognitive Supplement Research
09/03/2026
A 2026 informational consumer research report examining FocusMax cognitive support marketing claims, ingredient-level research context, proprietary blend transparency, pricing disclosures, and verification [...]
Update: Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma
09/03/2026
PARIS, FRANCE, 09 March 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it is voluntarily withdrawing Tazverik ® (tazemetostat) in all indications from all Ipsen markets. Ipsen’s decision to withdraw is [...]
Transactions in Connection with Share Buy-back Program
09/03/2026
Company Announcement COPENHAGEN, Denmark; March 9, 2026 – Genmab A/S (Nasdaq: GMAB). On February 17, 2026, Genmab announced the initiation of a share buy-back program to repurchase up to 342,130 shares with a maximum [...]
Valneva to Report Full Year 2025 Consolidated Financial Results on March 18, 2026
09/03/2026
Lyon (France), March 9 , 202 6 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it will report its full year 2025 financial results on Wednesday, March 18, 2026. The [...]
EssilorLuxottica: Déclaration de transactions sur actions propres
09/03/2026
Déclaration de transactions sur actions propres Paris, France (9 mars 2026, 18h00) – Conformément à l’autorisation octroyée par l’Assemblée Générale du 30 avril 2025, EssilorLuxottica déclare que du 2 mars 2026 au 4 [...]
EssilorLuxottica: Disclosure of transactions in own shares
09/03/2026
Disclosure of transactions in own shares Paris, France (March 9, 2026 - 6:00 pm) – In accordance with the authorization granted by the Annual Shareholders’ Meeting on April 30, 2025, EssilorLuxottica declares that from [...]
GENFIT Receives FDA Orphan Drug Designation for NTZ for the treatment of ACLF
09/03/2026
FDA grants Orphan Drug Designation (ODD) for NTZ for ACLF, a severe condition with no approved therapies NTZ is being advanced in ACLF through its G1090N reformulation, designed to unlock its clinical potential for [...]
Zealand Pharma to participate in upcoming investor conferences in March 2026
09/03/2026
Press release – No. 5 / 2026 Zealand Pharma to participate in upcoming investor conferences in March 2026 Copenhagen, Denmark, March 9, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology [...]
GENFIT reçoit la désignation Orphan Drug de la FDA pour NTZ dans le traitement de l’ACLF
09/03/2026
La FDA accorde la désignation Orphan Drug (ODD) à NTZ dans l'ACLF, syndrome grave pour lequel il n'existe aucun traitement approuvé NTZ est développé dans l'ACLF via sa nouvelle formulation G1090N, conçue pour optimiser [...]
Glaucoma Research Foundation and Alcon Partner to Expand Access to Trusted Glaucoma Education
09/03/2026
New English and Spanish editions of Understanding and Living with Glaucoma and first-ever Spanish audiobook aim to reach high-risk Hispanic communities Resources will be available during Glaucoma Awareness Week [...]
Radiant Health Centers Announces Honorees for 40th Annual Gala Celebrating Four Decades of Compassionate Care
09/03/2026
Jai Rodriguez and Harper Steele Headline Evening Honoring Cultural Impact, Legacy Leadership, and Community Hope Irvine, CA, March 09, 2026 (GLOBE NEWSWIRE) -- Radiant Health Centers , Orange County’s largest provider [...]
Surgery Partners, Inc. to Present at Upcoming Investor Conference
09/03/2026
BRENTWOOD, Tenn., March 09, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), is scheduled to meet with investors at the Barclays 28 th Annual Global Healthcare [...]
Hydration Room Opens in San Francisco’s Cow Hollow, Introducing Nurse-Administered, Medically Supervised IV Therapy Designed for Sustained Performance and Recovery
09/03/2026
New Union Street clinic delivers personalized hydration, immunity and performance support designed for sustained energy and resilience SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Hydration Room , a leading [...]
Valneva publiera ses résultats financiers consolidés 2025 le 18 mars 2026
09/03/2026
Lyon (France), le 9 mars 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA, société spécialisée dans les vaccins, a annoncé aujourd'hui qu’elle publiera ses résultats financiers pour l’exercice 2025 le mercredi 18 [...]
CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
09/03/2026
Following End-of-Phase 2 meeting, MBX remains on track to initiate Phase 3 in Q3 2026 In the fourth paragraph, we are replacing milligrams with micrograms . The corrected press release follows. CARMEL, Ind., March 09, [...]
Galecto Announces Name Change to Damora Therapeutics with Mission to Fundamentally Redefine Care for Patients with Blood Disorders
09/03/2026
-- Company will trade on Nasdaq under trading symbol "DMRA" effective March 10, 2026 -- -- On track to submit IND or CTA for DMR-001 in mutant-calreticulin essential thrombocythemia and myelofibrosis in mid-2026, with [...]
LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors
09/03/2026
Dr. Robert Lenz brings over 20 years of experience in neuroscience drug development NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late- [...]

Pages